Successful long-term disease-free survival following multimodal treatments in a patient with a repeatedly recurrent refractory adrenal cortical carcinoma

International Journal of Urology

Volumn 10, Issue 8, 2003, Pages 445-448

  Fujii, Yasuhisa ^a   Kageyama, Yukio ^a   Kawakami, Satoru ^a   Masuda, Hitoshi ^a   Arisawa, Chizuru ^a   Akamatsu, Hideki ^a   Akashi, Takumi ^a   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Adrenal cortical carcinoma; Multimodal treatments; Radiochemotherapy; Surgery; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE;

ADRENAL CORTEX CARCINOMA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; HUMAN; IRRADIATION; LONG TERM CARE; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; MUSCLE RESECTION; PRIORITY JOURNAL; PSOAS MUSCLE; RIB; STEM CELL TRANSPLANTATION;

ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOGRAPHY, ABDOMINAL; RECURRENCE; THORACIC SURGICAL PROCEDURES; TREATMENT OUTCOME;

EID: 0042382891     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2003.00651.x     Document Type: Article

References (14)

1. Sakamoto K, Ariyoshi A, Okazaki M. Metastatic adrenocortical carcinoma treated by repeated resection: a case report of long-term survival over 18 years. Int. J. Urol. 1995; 2: 50-2.
2. Sakai N, Yamada T, Asao T, Murayama T. Aldosterone-producing adrenocortical carcinoma metastases found seven years after adrenalectomy. Int. J. Urol. 1997; 4: 79-82.
3. Lewinsky BS, Grigor KM, Symington T, Neville AM. The clinical and pathologic features of 'non-hormonal' adrenocortical tumors. Report of twenty new cases and review of the literature. Cancer 1974; 33: 778-90.
4. King DR, Lack EE. Adrenal cortical carcinoma. A clinical and pathologic study of 49 cases. Cancer 1979; 44: 239-44.
5. Didolkar MS, Bescher RA, Elias EG, Moore RH. Natural history of adrenal cortical carcinoma, a clinicopathologic study of 42 patients. Cancer 1981; 47: 2153-61.
6. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am. J. Surg. Pathol. 1989; 13: 202-6.
7. Kopf D, Goretzki PE, Lehnert H. Clinical management of malignant adrenal tumors. J. Cancer Res. Clin. Oncol. 2001; 127: 143-55.
8. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992; 112: 963-70.
9. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann. Surg. Oncol. 1999; 6: 719-26.
10. Johnson DH, Greco FA. Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer 1986; 58: 2198-202.
11. Zidan J, Shpendler M, Robinson E. Treatment of metastatic adrenal cortical carcinoma with etoposide (VP-16) and cisplatin after failure with o,p'DDD. Clinical case reports. Am. J. Clin. Oncol. 1996; 19: 229-31.
12. Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH, Crawford ED. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 2000; 88: 1159-65.
13. Venkatesh S, Hickey RC, Sellin RV, Fernandez JF, Samaan NA. Adrenal cortical carcinoma. Cancer 1989; 64: 765-9.
14. Kageyama Y, Okada Y, Arai G et al. Preoperative concurrent chemoradiotherapy against muscle-invasive bladder cancer: results of partial cystectomy in elderly or high-risk patients. Jpn. J. Clin. Oncol. 2000; 30: 553-6.